The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Opgenra eptotermin alfa | Olympus Biotech International Limited | Spondylolisthesis | 🇪🇺 EU 2009-02-19 | Order → |
| Thymanax agomelatine | Servier (Ireland) Industries Ltd | Depressive Disorder, Major | 🇪🇺 EU 2009-02-19 | Order → |
| Valdoxan agomelatine | Les Laboratoires Servier | Depressive Disorder, Major | 🇪🇺 EU 2009-02-19 | Order → |
| Firmagon degarelix | Ferring Pharmaceuticals A/S | Prostatic Neoplasms | 🇪🇺 EU 2009-02-17 | Order → |
| Filgrastim Hexal filgrastim Biosimilar | Hexal AG | Hematopoietic Stem Cell Transplantation; Cancer | 🇪🇺 EU 2009-02-06 | Order → |
| Zarzio filgrastim Biosimilar | Sandoz GmbH | Hematopoietic Stem Cell Transplantation; Cancer | 🇪🇺 EU 2009-02-06 | Order → |
| Nplate romiplostim | Amgen Europe B.V. | Purpura, Thrombocytopenic, Idiopathic | 🇪🇺 EU 2009-02-04 | Order → |
| Rasilez HCT aliskiren;hydrochlorothiazide | Noden Pharma DAC | Hypertension | 🇪🇺 EU 2009-01-16 | Order → |
| RoActemra tocilizumab | Roche Registration GmbH | Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid; Cytokine Release Syndrome; Giant Cell Arteritis; COVID-19 virus infection | 🇪🇺 EU 2009-01-16 | Order → |
| Stelara ustekinumab | Janssen-Cilag International NV | Psoriasis; Arthritis, Psoriatic; Crohn Disease; Colitis, Ulcerative | 🇪🇺 EU 2009-01-16 | Order → |
| Pramipexole Teva pramipexole Generic | Teva Pharma B.V. | Parkinson Disease | 🇪🇺 EU 2008-12-18 | Order → |
| Vidaza azacitidine Accelerated assessment | Bristol-Myers Squibb Pharma EEIG | Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | 🇪🇺 EU 2008-12-17 | Order → |
| Kuvan sapropterin | BioMarin International Limited | Phenylketonurias | 🇪🇺 EU 2008-12-02 | Order → |
| Ifirmasta (previously Irbesartan Krka) irbesartan Generic | KRKA tovarna zdravil d.d. Novo mesto | Hypertension | 🇪🇺 EU 2008-12-01 | Order → |
| Icandra (previously Vildagliptin / metformin hydrochloride Novartis) vildagliptin;metformin | Novartis Europharm Limited | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2008-11-30 | Order → |
| Zomarist vildagliptin;metformin | Novartis Europharm Limited | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2008-11-30 | Order → |
| Azarga brinzolamide;timolol | Novartis Europharm Limited | Glaucoma, Open-Angle; Ocular Hypertension | 🇪🇺 EU 2008-11-25 | Order → |
| Jalra vildagliptin | Novartis Europharm Limited | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2008-11-19 | Order → |
| Xiliarx vildagliptin | Novartis Europharm Limited | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2008-11-19 | Order → |
| Zypadhera olanzapine | CHEPLAPHARM Registration GmbH | Schizophrenia | 🇪🇺 EU 2008-11-19 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.